China's CStone Pharma raises $150M to fund early stage I/O work


CStone Pharmaceuticals has raised $150 million in Series A funds to hunt for early stage candidates across therapeutic areas with immuno-oncology serving as a core focus. The privately-held firm incorporated in Hong Kong late last year roped in leading China-focused investors and a top Asia R&D hand.

Oriza Seed Venture Capital, Boyu Capital and WuXi Healthcare Ventures joined in the round for RMB975 million, according to a release that added a former Sanofi ($SNY) R&D executive, Frank Jiang, will hold the post of CEO.

Jiang's most recent post for the past decade was as head of Asia-Pacific R&D for Sanofi with responsibility for clinical trials ranging from Phase I to IV resulting in "several dozen product registrations," according to a release.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The company said that in addition to its immuno-oncology focus, CStone has an unspecified pipeline in cardiovascular diseases, rheumatoid arthritis, hematology and autoimmune diseases.

"With immuno-oncology as CStone's core therapeutic focus, the company strives to lead Chinese research to the global market through its world class R&D team, its innovative portfolio, and an open innovation strategy," the company said.

"The funds raised will be used to help accelerate multiple programs of the company into the clinical stage while at the same time seeking out new innovations from around the world for patients in China, and ultimately worldwide."

The funding round follows an announcement last month that China's Hengrui Therapeutics has raised $100 million from HR Bio Holdings--a joint venture between China healthcare firm Jiangsu Hengrui Medicine (JHM--its parent company) and an undisclosed blue chip investment firm, with few details provided other than to note the company's pipeline includes a “number of clinical-stage oncology and immuno-oncology assets.”

- here's the release

Related Article:
Hengrui Therapeutics gains $100M investment to further cancer pipeline

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.